LEADER trial: Primary Outcome

Slides:

Advertisements

Similar presentations

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.

Advertisements

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Effects of amlodipine plus telmisartan or amlodipine plus amiloride regimen on blood pressure control in hypertensive patients: preliminary report of Chinese.

Cholesterol quintile (mg/dL)

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Randomized, double-blind, multicenter, controlled trial.

Clinical Outcomes with Newer Antihyperglycemic Agents

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.

Study Design Scirica BM, Bhatt DL Braunwald et al, Sexagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med

SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC Time (days)

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.

Clinical Outcomes with Newer Antihyperglycemic Agents

Discontinuation of medication after nonfatal event: MI

Clinical Outcomes with Newer Antihyperglycemic Agents

Mikhail Kosiborod, MD Professor of Medicine (Cardiology)

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

Cardiovascular Outcomes Trials with Antihyperglycemic Agents

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Pravastatin in Elderly Individuals at Risk of Vascular Disease

New Insights from EXSCEL

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

First time a CETP inhibitor shows reduction of serious CV events

TNT: Baseline and final LDL cholesterol levels

on behalf of the LEADER Trial Steering Committee and Investigators

Managing Complex Hypertension: What Every Physician Should Know

Managing Hard-To-Treat Hypertension: What Every Physician Should Know

Baseline characteristics of patients

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

The Hypertension in the Very Elderly Trial (HYVET)

LIFE: Reduction in primary end-point events seen with reduction of LVH by two electrocardiographic criteria End point % reduction with each 1050-mm x ms.

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

ASCOT-BPLA: Primary and secondary end points

Relative risk of major events with atenolol vs placebo

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

Preventive Angioplasty in Myocardial Infarction Trial

4D trial: Primary end point

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

(p for noninferiority < 0.001)

Potential mechanisms whereby statins may reduce the risk of stroke

ARISE Trial Aggressive Reduction of Inflammation Stops Events

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Berger JS, et al. JAMA 2009;301:

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Collet JP, et al. Lancet 2009;373:309-17

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

Comparison of Baseline Characteristics by Primary End Point

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

FIELD: Primary outcome

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Fig. 1. The composite analysis of the risk of major adverse cardiovascular events (MACEs) from three cardiovascular outcome trials, expressed as relative.

Presentation transcript:

LEADER trial: Primary Outcome First occurrence of CV death, nonfatal myocardial infarction, or nonfatal stroke in the time-to-event analysis in patients with type 2 diabetes and high CV risk. Hazard ratio, 0.87 (95% CI, 0.78–0.97) P<0.001 for noninferiority P=0.01 for superiority Patients with an event (%) Placebo Liraglutide Months since randomisation Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial Adapted from: Marso SP et al., NEJM 2016

LEADER trial: Death from Cardiovascular Causes Hazard ratio, 0.78 (95% CI, 0.66–0.93) P=0.007 Placebo Patients with an event (%) Liraglutide Months since randomisation Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial Adapted from: Marso SP et al., NEJM 2016